KGK Science Secures Strategic Growth Investment from Maxim Partners

KGK Science Inc., a prominent North American contract research organization (CRO), has recently secured a significant growth investment from Maxim Partners. This milestone, finalized on June 30, 2026, positions KGK to enhance its capabilities in clinical trials and regulatory services, essential for the dietary supplement, nutraceutical, and consumer health sectors.

Founded in 1997 and headquartered in London, Ontario, KGK has built a robust reputation since its inception. With over 400 clinical trials completed across more than 40 health conditions and having published upwards of 150 peer-reviewed articles, KGK plays an integral role in helping consumer health companies validate their products scientifically.

The investment from Maxim Partners will primarily facilitate KGK's expansion in several key areas. This includes boosting its clinical trial capacity, increasing investment in decentralized and virtual trial methodologies, enhancing regulatory services, and fostering organizational growth. The existing leadership team, under the guidance of Founder and CEO Najla Guthrie, will continue to steer the company into its next growth phase.

Najla Guthrie expressed her enthusiasm regarding this investment, stating, “For nearly three decades, KGK has been committed to assisting consumer nutrition companies in generating the scientific evidence necessary for innovative product launches. This funding marks an exciting new chapter for us, as Maxim aligns with our long-term vision and brings valuable strategic resources to our operations.”

Maxim Partners, based in Chicago, focuses on investing in areas that impact health and nutrition. Gregg Wilson, the firm's Founder and Managing Partner, highlighted KGK's established reputation. He conveyed confidence that KGK is well-positioned to handle the increasing demand for scientifically validated nutrition products and emphasized the firm’s commitment to supporting KGK’s strategic growth initiatives.

With this investment, KGK aims to further strengthen its platform of scientific rigor and regulatory expertise that has garnered trust among clients. This strategic step underscores the growing recognition of the vital role that scientifically backed consumer nutrition products play in today’s marketplace.

In addition to the investment details, it is important to acknowledge the collaborative efforts of MLT Aikins, which served as legal counsel to Maxim Partners during this transaction. As the sector continues to evolve and consumer expectations grow, KGK Science's ability to adapt and innovate will be paramount to its success.

For more information about KGK Science and their offerings in the nutraceutical and health industry, you can visit their official website. To understand more about Maxim Partners and their investment focus areas, check their website.